MEK and Autophagy Inhibition in Metastatic/Locally Advanced, Unresectable Neuroblastoma RAS (NRAS) Melanoma
Condition:   Metastatic NRAS Melanoma Interventions:   Drug: Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 1);   Drug: Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 2);   Drug: Trametinib plus hydroxychloroquine in patients with NRAS Melanoma (Dose 3) Sponsor:   Hospices Civils de Lyon Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 7, 2019 Category: Research Source Type: clinical trials

PHASE I Clinical Study: Safety Evaluation of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTA0-Tyr3-Octreotate for Refractory or Recurrent Metastatic Neuroblastoma Expressing Somatostatin Receptors
Condition:   Neuroblastoma Intervention:   Drug: PRRT with 177Lu-DOTATATE Sponsor:   Institut Claudius Regaud Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 29, 2019 Category: Research Source Type: clinical trials

Safety Evaluation of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTA0-Tyr3-Octreotate for Refractory or Recurrent Metastatic Neuroblastoma Expressing Somatostatin Receptors
Condition:   Neuroblastoma Intervention:   Drug: PRRT with 177Lu-DOTATATE Sponsor:   Institut Claudius Regaud Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 29, 2019 Category: Research Source Type: clinical trials

Biomarkers of Renal Dysfunction in Neuroblastoma Survivors
Condition:   Neuroblastoma Survivors Intervention:   Other: Urine sample Sponsor:   Memorial Sloan Kettering Cancer Center Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 13, 2019 Category: Research Source Type: clinical trials

Dosimetry Guided PRRT With 177Lu-DOTATATE in Children
Conditions:   Neuroendocrine Tumors;   Neuroblastoma;   Pheochromocytoma;   Paraganglioma Interventions:   Drug: 177Lu-DOTA-tyr3-OCTREOTATE;   Procedure: Peptide Receptor Radiotherapy (PRRT) Sponsors:   Sue O'Dorisio;   Advanced Accelerator Applications Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 22, 2019 Category: Research Source Type: clinical trials

Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers
Conditions:   Neuroblastoma;   Osteosarcoma;   Other Solid Tumor Cancers Interventions:   Biological: Humanized 3F8 Bispecific Antibody;   Other: Blood draw Sponsor:   Memorial Sloan Kettering Cancer Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 1, 2019 Category: Research Source Type: clinical trials